Condition: Chronic Myeloid Leukemia, Chronic Phase · CML, Chronic Phase · CML, Refractory · Sponsor: Il-Yang Pharm. Co., Ltd.
In a multinational, multicenter, single-arm, open-label and Phase III Radotinib clinical study, chronic phase Ph+ chronic myeloid leukemia patients with failure or intolerance to previous TKIs therapy including Imatinib will be recruited. In this phase 3 study, 173 subjects are expected to be enrolled in a single arm with the administration of Radotinib 400mg twice daily, which includes 10% of dropout rate.
This description comes directly from the study's public registry record.
Na Yun Kim · +82.70.7165.7316 · nykim@ilyang.co.kr
Kang Hi An · +82.70.7165.7322 · khan@ilyang.co.kr
Always discuss trial participation with your own doctor first.
| Territorial State Budgetary Institution | Barnaul, Russia | Not Yet Recruiting |
| Federal State Budgetary Institution of Science | Kirov, Russia | Recruiting |
| Federal State Budgetary Institution | Moscow, Russia | Not Yet Recruiting |
| Hematology Centre based on City Clin. Hosp. n.a. S.P. Botkin | Moscow, Russia | Recruiting |
| Federal State Budgetary Institution | Saint Petersburg, Russia | Recruiting |
| Federal State Budgetary Institution | Saint Petersburg, Russia | Recruiting |
| Uijeongbu Eulji Medical Center, Eulji University | Uijeongbu-si, Gyeonggi-do, South Korea | Recruiting |
| Ankara University Medical Faculty | Ankara, Turkey (Türkiye) | Recruiting |
| Gazi University Medical Faculty | Ankara, Turkey (Türkiye) | Recruiting |
| Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty | Istanbul, Turkey (Türkiye) | Recruiting |
| Ege University Medical Faculty | Izmir, Turkey (Türkiye) | Recruiting |
| Mersin University Medical Faculty | Mersin, Turkey (Türkiye) | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03459534